ido-1-in-1

IDO1-IN-1 (2 HzBTZ) is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.

IDO1-IN-11 is an IDO1 inhibitor with an IC50 value of 0.6 nM.

IDO1-IN-12 is a potent oral inhibitor of IDO1 (indoleamine 2,3-dioxygenase 1).

IDO1-IN-14 (compound 4a) is a highly effective inhibitor of the IDO1 enzyme with an IC50 value of 396.9 nM and exhibits excellent suppression of cellular IDO1 activity in HeLa cells with an EC50 value of 3393 nM [1].

IDO1-IN-15 is an effective IDO1 inhibitor with IC50 of 127 nM. The potency of IDO1-IN-15 against IDO1 enzyme is comparable with Epacadostat in vitro.

IDO1-IN-18 (Compound 14) is a potent IDO1 inhibitor with potential applications in cancer research.

IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC50 of 61.6 nM. It inhibits cell IDO1 with an EC50 of 30 nM for HeLa cells and reduces the kyn/trp ratio by 51% in SK-OV-3 xenograft tumor tissue.

IDO1-IN-19 (Compound 17) is a potent IDO1 inhibitor with potential applications in cancer research.

IDO1-IN-16 (I-1) is an IDO1 inhibitor, targeting holo-IDO1 with an IC50 of 127 nM.

IDO1-IN-17 (I-4) is an IDO1 inhibitor with an IC50 of 0.44 μM in HeLa cells.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

IDO-IN-1 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with IC50 values of 59 nM for human IDO enzymatic activity and 12 nM for HeLa cell assays.

IDO-IN-13 (GS-4361) is a potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor (EC50: 17 nM).

IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor.

IDO-IN-5 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO-IN-8 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO/TDO-IN-1 is an orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50s: 9.7 and 47 nM).

IDO1-IN-2 is a potent and selective IDO1 inhibitor with IC50s of 81 nM, 59 nM (mouse), and 28 nM (rat), respectively. It has anti-cancer activity.

LY3381916 is a selective, potent and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.

(Rac)-IDO1-IN-5 is a racemate of IDO1-IN-5, a potent, selective, and brain-penetrating inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity. It specifically binds to apo-IDO1, which lacks heme, instead of mature heme-bound IDO1.

(S)-IDO1-IN-5 is an active S-isomer of IDO1-IN-5. (S)-IDO1-IN-5 binds to IDOL(IC50 value less than 1.5 µΜ).

IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug that suppresses IDO expression. It induces apoptosis, reduces mitochondrial membrane potential, and inhibits tumor cell migration and invasion. Additionally, IDOi-Pt(IV) prodrug-1 triggers reactive oxygen species-mediated endoplasmic reticulum stress and the secretion of damage-associated molecular patterns (DAMPs), leading to immunogenic cell death (ICD). Compared to cisplatin, IDOi-Pt(IV) prodrug-1 exhibits relatively high efficiency and low toxicity in its antitumor activity.

Benzomalvin C is a weak antagonist of the neurokinin-1 (NK1) receptor, inhibiting binding of substance P by 46% at 100 μg/ml in vitro, and a weak inhibitor of indolamine 2,3-dioxygenase (IDO) with an IC50 value of 130 μM for recombinant IDO. Isolated from Penicillium, it contains an epoxide group at C-19 and C-20, absent in benzomalvins A, B, or E.

Acid secretion-IN-1, a polycyclic compound, is synthesized for its application as an IDO inhibitor in synthetic experiments.